What to Do When H1 Antihistamine Therapy for Angioedema Has Not Achieved Symptom Control

H1 antihistamines are the cornerstone of initial therapy for angioedema and urticaria. When this first-line approach does not deliver adequate relief, an evidence-based escalation step is indicated. This protocol defines that next step.

Previous Treatment Line — Goals Not Achieved

H1 antihistamine therapy — including first-generation agents (diphenhydramine, hydroxyzine), second-generation agents (loratadine, cetirizine, desloratadine, fexofenadine), or doxepin hydrochloride as an alternative — did not achieve relief of pruritus or adequate reduction in the number, size, and duration of urticarial skin lesions.

Next-Line Approach

This protocol involves augmenting the existing antihistamine regimen with a complementary class of histamine receptor antagonist. This combination approach has demonstrated benefit in patients with urticaria whose symptoms remained uncontrolled on H1 therapy alone — the full regimen is in the protocol below.

Instant Access to Structured Evidence-Based Regimens

References

For patients whose symptoms are not controlled with an H1 antagonist, the addition of an H2 antagonist may be beneficial.
The combination of H1 and H2 antagonists has been demonstrated to be beneficial to patients with urticaria.
For patients whose symptoms are not controlled with an H1 antagonist, add an H2 antagonist to the treatment regimen.

View source ↗